Telomir Pharmaceuticals (NASDAQ:TELO - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.05), Zacks reports.
Telomir Pharmaceuticals Trading Down 3.3 %
Shares of TELO traded down $0.15 during trading hours on Friday, hitting $4.37. The company had a trading volume of 167,368 shares, compared to its average volume of 103,438. The company has a market capitalization of $130.05 million and a PE ratio of -7.53. Telomir Pharmaceuticals has a one year low of $3.11 and a one year high of $20.72. The company's fifty day moving average price is $4.76 and its two-hundred day moving average price is $4.82.
Telomir Pharmaceuticals Company Profile
(
Get Free Report)
Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.
Recommended Stories
Before you consider Telomir Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telomir Pharmaceuticals wasn't on the list.
While Telomir Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
